Adial Pharmaceuticals Stock (NASDAQ:ADIL)

Ownership Financials Chart

Previous Close

$0.73

52W Range

$0.58 - $3.00

50D Avg

$0.74

200D Avg

$0.96

Market Cap

$4.71M

Avg Vol (3M)

$816.00K

Beta

1.26

Div Yield

ADIL Company Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jul 27, 2018

Website

ADIL Performance

ADIL Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-8.28M	$-6.89M	$-13.32M
Net Income	$-13.20M	$-7.00M	$-12.73M
EBITDA	$-8.28M	$-7.00M	$-13.32M
Basic EPS	$-0.71	$-5.44	$-11.98
Diluted EPS	$-0.71	$-5.44	$-11.98

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
HOTH	Hoth Therapeutics, Inc.
RNAZ	TransCode Therapeutics, Inc.
TNXP	Tonix Pharmaceuticals Holding Corp.
ADTX	Aditxt, Inc.
VRAX	Virax Biolabs Group Limited
ALRN	Aileron Therapeutics, Inc.
REVB	Revelation Biosciences, Inc.
KTTA	Pasithea Therapeutics Corp.
RVPH	Reviva Pharmaceuticals Holdings, Inc.
BPTH	Bio-Path Holdings, Inc.
RNXT	RenovoRx, Inc.
ATXI	Avenue Therapeutics, Inc.
BNTC	Benitec Biopharma Inc.